Use apolipoprotein parameters and endpoints in drug development and approval processes

被引：6

作者：

Alaupovic, P ^{[1
]}

机构：

[1] Oklahoma Med Res Fdn, Lipid & Lipoprot Lab, Oklahoma City, OK 73104 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 1998年 / 81卷 / 8A期

关键词：

D O I：

10.1016/S0002-9149(98)00260-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：40F / 47F

页数：8

共 113 条

[11] AVOGARO P, 1983, RES CLIN LAB, V13, P431
[12] VALUES OF APO-AI AND APO-B IN HUMANS ACCORDING TO AGE AND SEX
AVOGARO, P
CAZZOLATO, G
BITTOLOBON, G
BELUSSI, F
QUINCI, GB
[J]. CLINICA CHIMICA ACTA, 1979, 95 (02) : 311 - 315
[13] RELATIONSHIP BETWEEN APOLIPOPROTEINS AND CHEMICAL-COMPONENTS OF LIPOPROTEINS IN SURVIVORS OF MYOCARDIAL-INFARCTION
AVOGARO, P
BITTOLOBON, G
CAZZOLATO, G
RORAI, E
[J]. ATHEROSCLEROSIS, 1980, 37 (01) : 69 - 76
[14] APOLIPOPROTEIN MEASUREMENTS IN CLINICAL BIOCHEMISTRY AND THEIR UTILITY VIS-A-VIS CONVENTIONAL ASSAYS
BACHORIK, PS
KWITEROVICH, PO
[J]. CLINICA CHIMICA ACTA, 1988, 178 (01) : 1 - 34
[15] BACHORIK PS, 1994, CLIN CHEM, V40, P1915
[16] POSTPRANDIAL EXCHANGE OF APOLIPOPROTEIN C-III BETWEEN PLASMA-LIPOPROTEINS
BARR, SI
KOTTKE, BA
MAO, SJT
[J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1981, 34 (02) : 191 - 198
[17] Bijvoet S, 1996, J LIPID RES, V37, P640
[18] CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS)
BLANKENHORN, DH
AZEN, SP
KRAMSCH, DM
MACK, WJ
CASHINHEMPHILL, L
HODIS, HN
DEBOER, LWV
MAHRER, PR
MASTELLER, MJ
VAILAS, LI
ALAUPOVIC, P
HIRSCH, LJ
[J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 969 - 976
[19] PREDICTION OF ANGIOGRAPHIC CHANGE IN NATIVE HUMAN CORONARY-ARTERIES AND AORTOCORONARY BYPASS GRAFTS - LIPID AND NONLIPID FACTORS
BLANKENHORN, DH
ALAUPOVIC, P
WICKHAM, E
CHIN, HP
AZEN, SP
[J]. CIRCULATION, 1990, 81 (02) : 470 - 476
[20] RADIOIMMUNOASSAY STUDIES OF HUMAN APOLIPOPROTEIN-E
BLUM, CB
ARON, L
SCIACCA, R
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1980, 66 (06) : 1240 - 1250

← 1 2 3 4 5 6 7 8 9 10 →